Usefulness of biodegradable stents constructed of poly-l-lactic acid monofilaments in patients with benign esophageal stenosis

Saito, Yasuharu; Tanaka, Toyohiko; Andoh, Akira; Matsui, Hideki; Hata, Kazunori; Tsujikawa, Tomoyuki; Nitta, Norihisa; Murata, Kiyoshi; Fujiyama, Yoshihide

doi:10.3748/wjg.v13.i29.3977

Cited by 124 publications

(76 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hyperplastic tissue ingrowth occurs in up to 50 % of SEMS placed for benign esophageal strictures [1]. While this tissue reaction is expected for biodegradable stents [5,6], ours is the first report of significant post-stent dysphagia due to stenosis. The early stent biodegradation should eliminate hyperplastic in-stent stenosis and the need for subsequent therapy.…”

mentioning

confidence: 61%

Severe hyperplastic tissue stenosis of a novel biodegradable esophageal stent and subsequent successful management with high-pressure balloon dilation

Hair

Devonshire

2010

Endoscopy

View full text Add to dashboard Cite

mentioning

confidence: 61%

Severe hyperplastic tissue stenosis of a novel biodegradable esophageal stent and subsequent successful management with high-pressure balloon dilation

Hair

Devonshire

2010

Endoscopy

View full text Add to dashboard Cite

“…Biodegradable stents offer an exciting solution in the future: extraction is unnecessary, and the normal airway is preserved after stent resorption. In human studies in benign oesophageal strictures, these stents have shown to be clinically effective [30].…”

Section: Discussionmentioning

confidence: 99%

Are metallic stents really safe? A long-term analysis in lung transplant recipients

Gottlieb¹,

Fuehner²,

Dierich³

et al. 2009

Eur Respir J

View full text Add to dashboard Cite

Airway complications affect 20% of all lung transplant recipients. Self-expandable metallic stents (SEMS) are one treatment option but their use in benign airway disorders is controversial. We studies the long-term safety of SEMS in lung transplant recipients.Between January 1998 and February 2008, all lung transplant recipients with SEMS were analysed retrospectively at a single centre. Complications were recorded until September 2008. In 65 (9.2%) out of 706 recipients, 111 (91% noncovered) bronchial SEMS were implanted a median (range) 133 (55-903) days after lung transplantation; follow-up was 777 (7-3.655) days. Clinical improvement was noted in 80% of recipients. The forced expiratory volume in 1 s increased by (mean¡SD) 21¡33%.Most frequent early complications were migration (3%) and mucus plugging (11%). No procedure-related deaths were noted. Re-stenosis occurred in 34 (52%) out of 65 recipients 85 (7-629) days after insertion. In multivariate analysis, stent insertion before post-operative day 90 was independently associated with an increased risk of re-stenosis (HR 3.29, 95% CI 1.50-7.18; p50.003). In 40% of recipients, new bacterial airway colonisation occurred after SEMS insertion. In SEMS patients, 5-yr survival was significantly lower than in the total cohort (60% versus 76%; p50.02).Late complications in lung transplant recipients treated with SEMS are frequent. The major problems are re-stenosis and airway colonisation.

show abstract

“…Of these, 14 articles met our inclusion criteria for the pooled analysis (Table 1). A total of seven studies reported results on BD stent placement [5][6][7][8][9][10][11], seven on SEMS placement for the treatment of benign esophageal disease [12][13][14][15][16][17][18].…”

Section: Literature Searchmentioning

confidence: 99%

Literature Analysis of the Treatment of Benign Esophageal Disease with Stent

et al. 2015

View full text Add to dashboard Cite

To analyze the efficacy and safety of benign esophageal disease used biodegradable (BD) stent or metal stent. The English literatures of benign esophageal disease that were treated by biodegradable or metal stents implantation were retrieved and summarized. In all 323 benign esophageal disease, the most common etiologies were benign refractory stricture, surgical anastomotic stricture and esophageal fistula/leak/perforation, but the main characteristics between the two groups were not significantly different. One hundred fifty-four cases were completely healed by using BD stents or self-expandable metal stents (SEMS) (47.7 %). Clinical success was achieved in 47.7 % of all patients and there was no significant difference between BD stents (51 %) and SEMS (46.2 %) (P=0.472), while stent migration occurred more frequently with SEMS (33.9 %) than with BD stent (19.6 %) (P≤ 0.05), and tissue in-or overgrowth occurred more frequently with SEMS (22.2 %) than with BD stents (8.8 %) (P≤0.05). Furthermore, the time about degradation of BD stents in esophageal was longer than removal of SEMS from the esophagus (P≤0.05). Placement of BD stents or SEMS provides effective and safe relief for benign esophageal disease. Clinical success and mortality were not significantly different. BD stents offers an advantage of fewer complications. Although stent placement is a viable strategy in patients with benign esophageal disease, the ideal treatment strategy and further randomized trials with large number of patients are needed.

show abstract

Usefulness of biodegradable stents constructed of poly-l-lactic acid monofilaments in patients with benign esophageal stenosis

Cited by 124 publications

References 22 publications

Severe hyperplastic tissue stenosis of a novel biodegradable esophageal stent and subsequent successful management with high-pressure balloon dilation

Severe hyperplastic tissue stenosis of a novel biodegradable esophageal stent and subsequent successful management with high-pressure balloon dilation

Are metallic stents really safe? A long-term analysis in lung transplant recipients

Literature Analysis of the Treatment of Benign Esophageal Disease with Stent

Contact Info

Product

Resources

About